Latest research finds that precision medicine can improve breast cancer treatment

The Ofweek medical network research found that doctors' recommendations and final treatment decisions are highly correlated with the results of the disease test, indicating that tumor genome testing can help doctors identify which patients can benefit the most from chemotherapy, and which patients can safely stop chemotherapy.

Most precision medical research in the cancer field targets patients who participate in clinical trials. Few studies have examined how doctors can use biomarker test results to recommend chemotherapy regimens and how to perform tests and final decisions based on patient experience. Researchers from the University of Michigan School of Nursing surveyed 3,880 women who received breast cancer treatment in 2013 and 2014. A total of 1,527 early-stage breast cancer patients responded to the survey, and 778 patients underwent a 21-gene recurrence score assay (RS) to assess the risk of disease recurrence and chemotherapy in estrogen receptor-positive breast cancer patients. Evaluation.

Overall, 47.2% of patients received advice not to receive chemotherapy, and 40.6% of patients recommended chemotherapy. The patient's recommendations were related to RS outcomes: almost all high-scoring patients received chemotherapy recommendations, and most patients who received low-risk outcomes received recommendations for no chemotherapy. At the same time, most patients with high scores eventually received chemotherapy, and almost no patients with low scores received chemotherapy. There are no substantial differences between races in terms of detection and treatment. Most patients were satisfied with RS scores and chemotherapy options.

“We found that most doctors performed tumor genome testing on patients as recommended by the professional guidelines. We also found that some patients did not follow the professional guidelines,” said Dr. Friese, who led the study. "For example, about 13% of women with breast cancer-positive women have a tumor genome test, but at present it is still not known whether these patients can benefit from the tests and recommendations."

The researchers also suggest that the oncology research community needs to do more to help patients understand the purpose of these tests, how to interpret the results, and what these results mean for their breast cancer treatment.

Rice Product

Rice Product,Organic Rice,Broken Rice,Rice Vermicelli

ZHONGSHAN G.H.L. TRADING CO., LTD. , https://www.ghltrade.com